ARPC5L

Across TCGA pan-cancer cohorts, ARPC5L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARPC5L data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARPC5L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARPC5L expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where ARPC5L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	1.000	0.899	.033	34	view →
PDAC	DFS	Quartile	All	0.465	0.277	.006	24	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.514	.022	13	view →
UCEC	DFS	Tertile	II,III,IV	0.916	0.529	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARPC5L–HNSC (DFS)

Open the HNSC breakdown →